sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.
|
tricyclic antidepressants
|
cimetidine
|
MECHANISM
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s27
|
DDI-DrugBank.d386.s27.p0
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
phenobarbital
|
acetaminophen
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p52
|
Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.
|
Ketoconazole
|
Isoniazid
|
INT
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s8
|
DDI-DrugBank.d187.s8.p2
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
simethicone
|
fosinopril
|
MECHANISM
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p30
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
Butalbital
|
chlordiazepoxide
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p6
|
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
|
Macrolide antibiotics
|
atorvastatin
|
MECHANISM
|
11197581.xml
|
DDI-MedLine.d25.s12
|
DDI-MedLine.d25.s12.p1
|
Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
|
Naproxen
|
beta-blockers
|
EFFECT
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s9
|
DDI-DrugBank.d85.s9.p2
|
However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.
|
quinolones
|
warfarin
|
EFFECT
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s10
|
DDI-DrugBank.d78.s10.p0
|
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
|
HMG-CoA reductase inhibitor
|
ketoconazole
|
ADVISE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s17
|
DDI-DrugBank.d140.s17.p0
|
Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
thyroid products
|
sympathomimetics
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s15
|
DDI-DrugBank.d460.s15.p9
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
sulfonylureas
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p21
|
These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.
|
ethinyl estradiol
|
contraceptive
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s46
|
DDI-DrugBank.d328.s46.p3
|
Sulfacetamide preparations are incompatible with silver preparations.
|
Sulfacetamide
|
silver
|
INT
|
Sulfacetamide_ddi.xml
|
DDI-DrugBank.d65.s0
|
DDI-DrugBank.d65.s0.p0
|
Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.
|
fluvoxamine
|
terbinafine
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s11
|
DDI-DrugBank.d76.s11.p0
|
Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
|
Azlocillin
|
netilmicin
|
ADVISE
|
Azlocillin_ddi.xml
|
DDI-DrugBank.d9.s0
|
DDI-DrugBank.d9.s0.p3
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ranitidine
|
sulfonamides
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1432
|
Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.
|
cyclosporine
|
quinolone class
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s6
|
DDI-DrugBank.d395.s6.p5
|
Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.
|
lithium
|
CELEBREX
|
ADVISE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s20
|
DDI-DrugBank.d172.s20.p0
|
On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.
|
bexarotene
|
bexarotene
|
NONE
|
Bexarotene_ddi.xml
|
DDI-DrugBank.d467.s2
|
DDI-DrugBank.d467.s2.p4
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
clarithromycin
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p2
|
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
|
diazepam
|
indomethacin
|
EFFECT
|
11210678.xml
|
DDI-MedLine.d67.s6
|
DDI-MedLine.d67.s6.p1
|
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
|
zalcitabine
|
aluminum
|
ADVISE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s23
|
DDI-DrugBank.d263.s23.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
clozapine
|
midazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p385
|
It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
|
neurotensin
|
enkephalins
|
EFFECT
|
6545985.xml
|
DDI-MedLine.d131.s3
|
DDI-MedLine.d131.s3.p0
|
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
loop diuretics
|
EFFECT
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s12
|
DDI-DrugBank.d162.s12.p4
|
This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
|
fluvoxamine
|
alprazolam
|
NONE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s17
|
DDI-DrugBank.d76.s17.p6
|
In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
|
captopril
|
nateglinide
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s11
|
DDI-DrugBank.d460.s11.p29
|
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
|
Ketoconazole
|
vitamin D
|
MECHANISM
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s8
|
DDI-DrugBank.d98.s8.p2
|
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
|
carboxymethylcellulose-cysteine
|
CMC-Cys
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s1
|
DDI-MedLine.d76.s1.p13
|
Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.
|
magnesium hydroxide
|
enoxacin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s17
|
DDI-DrugBank.d395.s17.p5
|
Patients on rifampin should receive 70 mg of CANCIDAS daily.
|
rifampin
|
CANCIDAS
|
ADVISE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s11
|
DDI-DrugBank.d350.s11.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
polymyxins
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p4
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
MAOIs
|
fluvoxamine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p11
|
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).
|
Trileptal
|
ethinylestradiol
|
NONE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s40
|
DDI-DrugBank.d307.s40.p5
|
Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).
|
Skeletal muscle relaxants
|
tubocurarine
|
NONE
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s12
|
DDI-DrugBank.d318.s12.p2
|
Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.
|
cephalosporins
|
furosemide
|
EFFECT
|
Cefepime_ddi.xml
|
DDI-DrugBank.d378.s1
|
DDI-DrugBank.d378.s1.p1
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
narcotic analgesics
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p4
|
Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.
|
TNF antagonist
|
ORENCIA
|
EFFECT
|
Abatacept_ddi.xml
|
DDI-DrugBank.d297.s3
|
DDI-DrugBank.d297.s3.p0
|
Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.
|
terfenadine
|
macrolide antibiotics
|
EFFECT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s10
|
DDI-DrugBank.d522.s10.p0
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
psychotropic medications
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p7
|
It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
|
neurotensin
|
tuftsin
|
EFFECT
|
6545985.xml
|
DDI-MedLine.d131.s5
|
DDI-MedLine.d131.s5.p0
|
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).
|
Diphenhydramine hydrochloride
|
alcohol
|
EFFECT
|
Diphenhydramine_ddi.xml
|
DDI-DrugBank.d296.s0
|
DDI-DrugBank.d296.s0.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
alprazolam
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p134
|
Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.
|
diltiazem
|
aprepitant
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s32
|
DDI-DrugBank.d382.s32.p0
|
Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
|
NSAIDs
|
methotrexate
|
MECHANISM
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s12
|
DDI-DrugBank.d85.s12.p7
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
lovastatin
|
digoxin
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p3
|
However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
|
theophylline
|
CGS 21680
|
NONE
|
7746025.xml
|
DDI-MedLine.d51.s4
|
DDI-MedLine.d51.s4.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
ibuprofen
|
anesthetics
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p959
|
A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.
|
Imitrex
|
dihydroergotamine
|
NONE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s4
|
DDI-DrugBank.d423.s4.p8
|
Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.
|
beta-agonists
|
non-potassium sparing diuretics
|
ADVISE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s5
|
DDI-DrugBank.d284.s5.p0
|
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.
|
steroidal anti-inflammatory agent
|
potassium sparing diuretics
|
EFFECT
|
Hydroflumethiazide_ddi.xml
|
DDI-DrugBank.d17.s25
|
DDI-DrugBank.d17.s25.p1
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
macrolide antibiotics
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p65
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
tetracycline
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p4
|
If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.
|
NPH human insulin
|
NovoLog
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s8
|
DDI-DrugBank.d313.s8.p2
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
propafenone
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p8
|
The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
|
olprinone
|
anagrelide
|
EFFECT
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s14
|
DDI-DrugBank.d75.s14.p13
|
Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
|
vitamin B12
|
folic acid
|
INT
|
Folic Acid_ddi.xml
|
DDI-DrugBank.d425.s1
|
DDI-DrugBank.d425.s1.p44
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
tricyclic antidepressants
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p5
|
The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
|
antiparkinsonian drug
|
amitriptyline
|
EFFECT
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s0
|
DDI-DrugBank.d86.s0.p11
|
Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.
|
Erythromycin
|
triazolam
|
MECHANISM
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s19
|
DDI-DrugBank.d522.s19.p3
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
polymyxins
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p5
|
Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.
|
Indinavir
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s34
|
DDI-DrugBank.d485.s34.p0
|
Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
|
estrogens
|
aluminum hydroxide
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s32
|
DDI-DrugBank.d558.s32.p47
|
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
|
aminoglycosides
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s2
|
DDI-DrugBank.d114.s2.p5
|
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.
|
indinavir
|
VIRACEPT
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s14
|
DDI-DrugBank.d340.s14.p4
|
Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
|
Sonata
|
thioridazine
|
EFFECT
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s8
|
DDI-DrugBank.d324.s8.p2
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
Arthropan
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p7
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
tiagabine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p38
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
nonsteroidal anti-inflammatory agents
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p0
|
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.
|
LEVSIN
|
tricyclic antidepressants
|
EFFECT
|
Hyoscyamine_ddi.xml
|
DDI-DrugBank.d142.s0
|
DDI-DrugBank.d142.s0.p5
|
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).
|
Gleevec
|
cyclosporine
|
ADVISE
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s9
|
DDI-DrugBank.d115.s9.p0
|
Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.
|
contraceptives
|
Estrogens
|
NONE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s17
|
DDI-DrugBank.d314.s17.p3
|
This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
|
salicylate
|
corticosteroid
|
EFFECT
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s5
|
DDI-DrugBank.d487.s5.p2
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
rifampin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p3
|
Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
|
benzodiazepines
|
SUBOXONE
|
ADVISE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s7
|
DDI-DrugBank.d380.s7.p0
|
Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
|
coumarin anticoagulant
|
lovastatin
|
EFFECT
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s15
|
DDI-DrugBank.d567.s15.p0
|
Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
|
Acetazolamide
|
sodium bicarbonate
|
EFFECT
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s13
|
DDI-DrugBank.d368.s13.p0
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
tranquilizers
|
CNS depressants
|
NONE
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p41
|
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.
|
amprenavir
|
rifabutin
|
NONE
|
11158747.xml
|
DDI-MedLine.d3.s3
|
DDI-MedLine.d3.s3.p0
|
Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
|
zaleplon
|
promethazine
|
MECHANISM
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s12
|
DDI-DrugBank.d324.s12.p3
|
This allows bitolterol to open air passages, increasing the effectiveness of the steroid.
|
bitolterol
|
steroid
|
EFFECT
|
Bitolterol_ddi.xml
|
DDI-DrugBank.d560.s2
|
DDI-DrugBank.d560.s2.p0
|
Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
|
morphine
|
dmPGE2
|
EFFECT
|
7625885.xml
|
DDI-MedLine.d128.s13
|
DDI-MedLine.d128.s13.p2
|
Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
|
amitriptyline HCl
|
anticholinergic
|
EFFECT
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s19
|
DDI-DrugBank.d99.s19.p0
|
Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.
|
diflunisal
|
hydrochlorothiazide
|
MECHANISM
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s5
|
DDI-DrugBank.d132.s5.p3
|
CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
|
CRIXIVAN
|
indinavir
|
EFFECT
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s63
|
DDI-DrugBank.d97.s63.p0
|
Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.
|
Tricyclic Antidepressants
|
imipramine
|
NONE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s15
|
DDI-DrugBank.d54.s15.p1
|
The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.
|
Adenocard
|
digitalis
|
EFFECT
|
Adenosine_ddi.xml
|
DDI-DrugBank.d226.s3
|
DDI-DrugBank.d226.s3.p0
|
Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.
|
Magnesium
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s5
|
DDI-DrugBank.d516.s5.p2
|
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.
|
HMG-CoA reductase inhibitor
|
cimetidine
|
ADVISE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s17
|
DDI-DrugBank.d140.s17.p2
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
alcohol
|
tricyclic antidepressants
|
NONE
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p28
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
aminoglycosides
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p1
|
This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.
|
alprazolam
|
Fluvoxamine
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s17
|
DDI-DrugBank.d76.s17.p7
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
itraconazole
|
protease inhibitors
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p747
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
analgesics
|
HMG-CoA reductase inhibitors
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p50
|
The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.
|
SULAR
|
atenolol
|
EFFECT
|
Nisoldipine_ddi.xml
|
DDI-DrugBank.d106.s7
|
DDI-DrugBank.d106.s7.p0
|
Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;
|
Phenobarbital
|
phenobarbital
|
NONE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s13
|
DDI-DrugBank.d438.s13.p0
|
Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
|
indomethacin
|
furosemide
|
ADVISE
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s17
|
DDI-DrugBank.d231.s17.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
indomethacin
|
methyldopa
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p992
|
In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.
|
enflurane
|
NIMBEX
|
ADVISE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s9
|
DDI-DrugBank.d60.s9.p1
|
Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.
|
ketoconazole
|
astemizole
|
EFFECT
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s5
|
DDI-DrugBank.d458.s5.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.